Hyzine-50®; QYS®; Vistacon®; Vistaquel®;
Hydroxyzine Hydrochloride; Hydroxyzine Pamoate|
Dental: Treatment of anxiety, as a preoperative sedative in pediatric
Medical: Treatment of anxiety; as a preoperative sedative; as an antipruritic
Unlabeled uses: Antiemetic; alcohol withdrawal symptoms
Hypersensitivity to hydroxyzine or any component
Causes sedation, caution must be used in performing tasks which require
alertness (ie, operating machinery or driving). Sedative effects of CNS
depressants or ethanol are potentiated. S.C., intra-arterial, and I.V.
administration are not recommended since thrombosis and digital gangrene can
occur; extravasation can result in sterile abscess and marked tissue induration;
should be used with caution in patients with narrow-angle glaucoma, prostatic
hypertrophy, and bladder neck obstruction; should also be used with caution in
patients with asthma or COPD.
Central nervous system: Drowsiness, headache, fatigue, nervousness, dizziness
Respiratory: Thickening of bronchial secretions
Neuromuscular & skeletal: Tremor, paresthesia, seizure
Ocular: Blurred vision
Symptoms of overdose include seizures, sedation, hypotension
There is no specific treatment for an antihistamine overdose, however, most
of its clinical toxicity is due to anticholinergic effects. Anticholinesterase
inhibitors may be useful by reducing acetylcholinesterase. For anticholinergic
overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or
0.02 mg/kg for children) I.V., slowly may be given to reverse these effects.
CNS depressants, anticholinergics, used in combination with hydroxyzine may
result in additive effects
Protect from light; store at 15°C to
30°C and protected from freezing; I.V. is
incompatible when mixed with aminophylline, amobarbital, chloramphenicol,
dimenhydrinate, heparin, penicillin G, pentobarbital, phenobarbital, phenytoin,
ranitidine, sulfisoxazole, vitamin B complex with C
Competes with histamine for H1-receptor sites on effector cells in
the gastrointestinal tract, blood vessels, and respiratory tract. Possesses
skeletal muscle relaxing, bronchodilator, antihistamine, antiemetic, and
Onset of effect: Within 15-30 minutes
Duration: 4-6 hours
Absorption: Oral: Rapid
Metabolism: Exact fate is unknown
Half-life: 3-7 hours
Time to peak serum concentration: Within 2 hours
Oral: 0.6 mg/kg/dose every 6 hours
I.M.: 0.5-1 mg/kg/dose every 4-6 hours as needed
Antiemetic: I.M.: 25-100 mg/dose every 4-6 hours as needed
Anxiety: Oral: 25-100 mg 4 times/day; maximum dose: 600 mg/day
Oral: 50-100 mg
I.M.: 25-100 mg
Management of pruritus: Oral: 25 mg 3-4 times/day
Dosing interval in hepatic impairment: Change dosing interval to
every 24 hours in patients with primary biliary cirrhosis
Alcohol: Additive CNS effect, avoid use
Relief of symptoms, mental status, blood pressure
|Dental Health: Local
No information available to require special precautions
Effects on Dental Treatment|
1% to 10% of patients experience dry mouth
Take this drug as prescribed; do not increase dosage or discontinue without
consulting prescriber. Store medication away from light. Maintain adequate
hydration (2-3 L/day of fluids unless instructed to restrict fluid intake). Void
before taking medication. Do not use excessive alcohol or other CNS depressants
or sleeping aids without consulting prescriber. May cause dizziness, drowsiness,
or blurred vision (use caution when driving or engaging in tasks requiring
alertness until response to drug is known); or nausea, dry mouth, appetite
disturbances (small frequent meals, frequent mouth care, or sucking hard candy
may help). Report unusual weight gain, unresolved nausea or diarrhea, chest pain
or palpitations, muscle or joint pain, excess sedation, sore throat, or
difficulty breathing. Pregnancy/breast-feeding precautions: Inform
prescriber if you are or intend to be pregnant. Consult prescriber if
Extravasation can result in sterile abscess and marked tissue induration;
provide safety measures (ie, side rails, night light, and call button); remove
smoking materials from area; supervise ambulation
Injection: 25 mg/mL (1 mL, 2 mL, 10 mL); 50 mg/mL (1 mL, 2 mL, 10 mL)
Syrup: 10 mg/5 mL (120 mL, 480 mL, 4000 mL)
Tablet: 10 mg, 25 mg, 50 mg, 100 mg
Capsule: 25 mg, 50 mg, 100 mg
Suspension, oral: 25 mg/5 mL (120 mL, 480 mL)
"Hydroxyzine Hydrochloride: Possible Adverse Cardiac Interactions,"
Psychopharmacol Comm, 1971, 1:61-5.
McKenzie R, Wadhwa RK, Uy NT, et al,
"Antiemetic Effectiveness of Intramuscular Hydroxyzine Compared With Intramuscular Droperidol,"
Anesth Analg, 1981, 60(11):783-8.
Paton DM and Webster DR,
"Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),"
Clin Pharmacokinet, 1985, 10(6):477-97.
"Neonatal Withdrawal Syndrome Associated With Hydroxyzine Hydrochloride," Am
J Dis Child, 1977, 131:529-30.
Simons FE, Simons KJ, and Frith EM,
"The Pharmacokinetics and Antihistaminic of the H1 Receptor Antagonist Hydroxyzine,"
J Allergy Clin Immunol, 1984, 73(1 Pt 1):69-75.
Simons KJ, Watson WT, Chen XY, et al,
"Pharmacokinetic and Pharmacodynamic Studies of the H1-Receptor Antagonist Hydroxyzine in the Elderly,"
Clin Pharmacol Ther, 1989, 45(1):9-14.
Tsukuda M, Furukawa S, Kokatsu T, et al,
"Comparison of Granisetron Alone and Granisetron Plus Hydroxyzine Hydrochloride for Prophylactic Treatment of Emesis Induced by Cisplatin Chemotherapy,"
Eur J Cancer, 1995, 31A(10):1647-9.
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved